The Burrill Report


The Burrill Report (January 30, 2012): What's Driving Roche's $5.7 Billion Bid for Illumina (.MP3,15.03 Mb)

Roche’s $5.7 billion hostile bid for the sequencing company Illumina could create a personalized medicine powerhouse capable of not only driving a transformation in the treatment of disease, but its diagnosis as well. Roche has big visions, but the deal has raised some eyebrows. We spoke to Chris Bowe, U.S. Healthcare analyst for Scrip about Roche’s efforts, what it means for personalized medicine, and what some other M&A activity tells us about the industry's changing landscape.

January 27, 2012
http://www.burrillreport.com/article-whats_driving_roches_5_7_billion_bid_for_illumina_.html